NAD+: The Energy Carrier at the Center of Aging Research

The short version

NAD+ stands for nicotinamide adenine dinucleotide, but the name is less important than the job: it is the cell's central rechargeable carrier, shuttling electrons from food to the machinery that makes ATP (the fuel every cell runs on). It also gets used up — consumed, not just cycled — by enzymes that govern DNA repair (PARPs), gene regulation (sirtuins), and inflammation (CD38). Because tissues lose NAD+ as we age, restoring that pool has become a major target in longevity research ^[11].

Here is where the evidence actually stands. Oral precursors — NMN and NR are the two most-studied — reliably raise blood NAD+ in humans ^[9][12]. A multicenter RCT found that 300-900 mg/day NMN for 60 days dose-dependently elevated blood NAD+ and improved walking distance and quality-of-life scores ^[9]. A separate study found that 250 mg/day NMN for 10 weeks improved muscle insulin sensitivity in prediabetic women ^[10]. But a 2025 narrative review in Nature Metabolism concluded that the broader human evidence base is still limited, that age-related NAD+ decline has been demonstrated consistently in only a few human studies, and that tissue-specific dynamics remain poorly characterized ^[8].

NAD+ itself (and its precursors NMN and NR) is marketed as a dietary supplement for human use. This page summarizes the published research. It is not medical advice and does not recommend any product or dose.

What it is

NAD+ is a dinucleotide built from two nucleotides joined by a pair of bridging phosphate groups: nicotinamide mononucleotide on one end and adenosine monophosphate on the other. Molecular formula C21H27N7O14P2. The nicotinamide (pyridine) ring in the NMN half is the business end: it accepts a hydride ion (H⁻, one proton plus two electrons) to become NADH, then donates it again in a downstream reaction, regenerating NAD+. That interconversion — NAD+ ↔ NADH — is the basis of the redox carrier function.

NAD+ is an endogenous molecule, present in every living cell. It is synthesized from dietary precursors (tryptophan, nicotinamide, nicotinic acid, NMN, NR) via the Preiss-Handler pathway, the de novo pathway, and the salvage pathway. The reduced form (NADH) carries electrons to the mitochondrial electron-transport chain, where they drive ATP synthesis. It is both a coenzyme and a signaling substrate — that dual role is what makes it unusual and relevant to aging research ^[11].

How it works

NAD+ has two distinct biochemical lives in the cell.

In its redox carrier role, it cycles continuously between its oxidized (NAD+) and reduced (NADH) forms — accepting hydrogen from glycolysis and the citric-acid cycle and delivering it to Complex I of the mitochondrial electron-transport chain. Without that delivery, the whole chain stalls and ATP production collapses.

In its signaling substrate role, NAD+ is consumed — irreversibly cleaved — by three classes of enzyme:

• Sirtuins (SIRT1-SIRT7): NAD+-dependent protein deacylases that regulate gene transcription, mitochondrial biogenesis, DNA repair, and inflammation. SIRT1 deacetylates histones and the transcription factor PGC-1α; SIRT3-SIRT5 regulate mitochondrial metabolism.
• PARPs (chiefly PARP1): consume NAD+ to build poly(ADP-ribose) chains on proteins near DNA breaks, coordinating damage repair. Under heavy DNA damage, PARP1 activity can rapidly deplete cellular NAD+.
• CD38 and CD157: NAD-consuming ectoenzymes that rise with age and inflammation, and are now considered the dominant driver of age-related NAD+ decline — more so than biosynthesis deficits ^[11].

NAMPT (nicotinamide phosphoribosyltransferase) is the rate-limiting enzyme in the NAD+ salvage pathway and a key determinant of cellular NAD+ levels.

What the research shows

Foundational biology. A comprehensive 2021 review in Nature Reviews Molecular Cell Biology established the competing-consumer model: sirtuins, PARPs and CD38/CD157 all draw from the same NAD+ pool, and age-related CD38 rise is now understood as a major driver of declining tissue NAD+. Declining NAD+ links to metabolic dysfunction and disease susceptibility across model organisms and humans ^[11].

NMN — a multicenter RCT. The highest-powered human trial of an NAD+ precursor enrolled middle-aged adults in a double-blind, placebo-controlled, parallel-group design across multiple centers. Oral NMN at 300, 600 or 900 mg/day for 60 days dose-dependently raised blood NAD+ at days 30 and 60 (p≤0.001 vs placebo at all doses). The 600 mg/day group showed the most favorable improvement in walking distance and quality-of-life scores; no safety issues were observed at any dose ^[9].

NMN — muscle insulin sensitivity. A smaller but mechanistically focused trial gave 250 mg/day NMN orally for 10 weeks to prediabetic postmenopausal women. The result was a significant increase in muscle insulin sensitivity measured by hyperinsulinemic-euglycemic clamp, and remodeling of insulin signaling in skeletal muscle, without changes in body composition or HbA1c ^[10].

NR — dose-response safety and pharmacology. In a randomized, placebo-controlled trial of healthy overweight adults, nicotinamide riboside at 100, 300 or 1000 mg/day for 8 weeks dose-dependently raised whole-blood NAD+ by 22%, 51% and 142% respectively, with no significant adverse effects at any dose, no LDL elevation, and no disruption of one-carbon metabolism ^[12].

The 2025 evidence summary. A narrative review published in Nature Metabolism synthesized the human clinical evidence on NAD+ precursor supplementation in aging. Its conclusions are notably measured: human trials have shown limited efficacy overall; age-related NAD+ decline has been demonstrated consistently in only a limited number of human studies; tissue-specific NAD+ dynamics remain poorly characterized; and the field still needs more clinical studies of systemic and tissue-specific metabolism rather than reliance on rodent extrapolation ^[8].

Reported effects, cautions & safety

NAD+ precursors have a large real-world user base, and several important cautions appear in the literature.

• Oral NAD+ itself is poorly bioavailable. Most researchers consider NMN and NR the rational oral approach; plain "NAD+" capsules may deliver little intact coenzyme to cells.
• Blood NAD+ vs. tissue NAD+ vs. clinical outcomes. Raising blood NAD+ is well demonstrated, but translation to hard clinical outcomes — longevity, disease prevention — has not been shown in humans. A 2025 Nature Metabolism review is explicit on this ^[8].
• Preclinical data may not translate. Much of the strongest longevity evidence comes from rodents and worms. Human biology may differ in ways that preclinical models do not capture.
• IV NAD+ carries specific risks. IV NAD+ wellness infusions are marketed aggressively, but infused NAD+ is rapidly cleared from plasma, and infusions can cause chest or abdominal discomfort, flushing and nausea at higher rates. A compounded injectable NAD+ product was subject to an FDA Class I recall for elevated bacterial endotoxin.
• Theoretical oncology concern. NAD+ supports rapidly proliferating cells. A theoretical concern exists that boosting NAD+ could fuel the metabolism of existing tumors; NAD+ plays context-dependent roles in cancer biology, and caution is warranted in oncology populations.
• NMN regulatory uncertainty. The FDA has taken the position that NMN is excluded from the dietary-supplement definition because it was investigated as a drug first, creating ongoing marketplace uncertainty.
• Supplement quality varies. Third-party testing is not guaranteed; actual content can differ from label claims.

Where it fits in longevity research

NAD+ is the desk's evidence anchor: the compound with the most human trial data, where blood-level endpoints are clear and reproducible even if the downstream clinical translation is still in debate ^[8][9][12]. Where MOTS-c is a novel mitochondrially-encoded signal with a rich mechanistic story but no human efficacy trials at all, NAD+ has randomized controlled trials, dose-response pharmacology, and a large supplement market. The comparison sharpens both pictures: MOTS-c shows how a mitochondrial signal could modulate energy sensing; NAD+ is the currency that energy sensing manages. See how they line up on the comparison page.